Press Archive 2008
IV Quarter:
12/18/08: DAIICHI SANKYO's Prasugrel receives positive opinion from the EU-Committee
12/15/08: DAIICHI SANKYO to acquire sales force from Merck Serono in France
12/07/08: DAIICHI SANKYO initiates Phase III trial of its investigational Factor Xa inhibitor
12/07/08: New Phase II data provide insight into optimal dosing of oral Factor Xa inhibitor
11/25/08: DAIICHI SANKYO sets up subsidiary in Ireland
11/13/08: Marketing approval for SEVIKAR® granted
11/11/08: DAIICHI SANKYO enters strategic R&D partnership with ArQule
11/05/08: DAIICHI SANKYO restructures European affiliates
11/03/08: Acquisition of Merck Serono’s cardio-metabolism sales force and products in Turkey
III Quarter:
09/02/08: DAIICHI SANKYO Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
07/21/08: DAIICHI SANKYO appoints general manager in Turkey
07/16/08: DAIICHI SANKYO plans to obtain sales force from Merck Pharma GmbH
07/07/08: DAIICHI SANKYO to implement carbon offset program
II Quarter:
06/25/08: DAIICHI SANKYO joins the IFPMA
06/23/08: FDA Extends Review Period for Prasugrel
06/15/08: OLMETEC® opens narrowed arteries in patients with hypertension
06/11/08: Ranbaxy to bring in DAIICHI SANKYO as Majority Partner
05/21/08: DAIICHI SANKYO aquires U3 Pharma AG
05/13/08: DAIICHI SANKYO sets up affiliate in Turkey
I Quarter:
03/05/08: DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly
02/21/08: FDA grants priority review for prasugrel
02/20/08: Marketing Authorization Application (MAA) submission of Prasugrel
01/04/08: DAIICHI SANKYO Submit New Drug Application for Investigational Antiplatelet
Further releases can be found in our press archive 2007.
